Benzinga | Feb 24, 2021 09:40AM EST

Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $205

Piper Sandler analyst David Amsellem maintains Jazz Pharmaceuticals (NASDAQ:JAZZ) with a Overweight and raises the price target from $175 to $205.